Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
Novavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.Build your future with us
Join other passionately curious people who are bringing innovative vaccines to the world
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Severe acute respiratory syndrome (SARS)
Severe acute respiratory syndrome coronavirus (SARS-CoV)
China, Hong Kong SAR, Taiwan, Singapore, Canada, limited cases in other countries in Asia, Europe, USA
Airborne route in droplets of saliva; hand contact with contaminated surfaces; trajectory of 2003 epidemic linked with air travel routes; distinct possibility of further outbreaks
- The 2003 SARS outbreak caused over 8000 infections and 800 deaths
- Case-fatality rate (CFR) estimated up to 9.6%
- Most patients were previously healthy adults aged 25–70 years
Before this century, coronaviruses were a relatively obscure family of viruses known to cause the common cold in humans.1 In 2002, a new coronavirus emerged, causing an epidemic outbreak of pneumonia, first reported in China, followed by other Asian countries, with several cases also appearing in Canada and the US.1 The outbreak was controlled by the strict isolation of patients, and the following year the virus was identified and characterized as Severe Acute Respiratory Syndrome coronavirus (SARS-CoV).1
What characterizes SARS?
SARS presents as a fever, shortness of breath, and lower respiratory tract infection, with some people also experiencing gastrointestinal complications.1 When studied using an electron microscope, coronaviruses appear as spherical particles covered in spikes—they look like the sun’s corona (atmosphere) or crown, hence the name “coronavirus.”1 Coronaviruses can infect many animal species.1,5 While in the original animal host, they undergo mutations and develop into new strains, which can spread to humans by touching a surface or object contaminated with infectious droplets and then touching one’s mouth, nose, or eyes or through droplets in the air—a process known as zoonotic transfer.1,6 These constantly evolving strains have the potential to cause severe respiratory diseases.6 Live animals handled by Chinese market traders were likely the zoonotic origin of SARS-CoV.1
Need for vaccine development
SARS-CoV has the potential to spread rapidly, cause death and disability, and disrupt economies, and so remains a serious public health concern.6 Currently, there is no antiviral therapy for SARS.1 While it is not clear whether SARS-CoV will again emerge into the human population, it is certain that the evolution and spread of new disease-causing coronaviruses, such as MERS (2012) and COVID-19 (2019), pose an ongoing threat to human health and survival. Because future global outbreaks remain an ominous scenario, effective vaccines against SARS-CoV and other coronaviruses will be an invaluable component of our defense against them.
- Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69:635–664.
- World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002–31 July 2003. 24 July 2015. Available at: https://www.who.int/publications/m/item/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003 [Accessed 27 Aug 2021].
- World Health Organization. Severe Acute Respiratory Syndrome (SARS). Available at: https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab_1 [Accessed 27 Aug 2021].
- Cherry JD. The chronology of the 2002–2003 SARS mini pandemic. Paediatr Respir Rev. 2004;5(4):262–269.
- Chang L, et al. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020;34:75–80.
- de Wilde AH, et al. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1–42.